Recruiting
Phase 2

NK Cell Therapy

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT02727803

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Acute Biphenotypic Leukemia

Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia in Remission

Acute Myeloid Leukemia With Myelodysplasia-Related Changes

Eligibility Criteria

Sex: All

Age: 15 - 70+

Healthy Volunteers: Not accepted

Interventions

Allogeneic Natural Killer Cell Line NK-92

Anti-Thymocyte Globulin

Busulfan

Clofarabine

Cyclophosphamide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-07. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-11-06.